注射用重组人干扰素α-1b联合蒙脱石散对轮状病毒性肠炎患儿肠黏膜损伤指标变化及免疫功能的影响  

Effect of recombinant human interferon alpha-1b combined with montelukast for injection on changes of intestinal mucosal damage indicators and immune function in children with rotavirus enteritis

作　　者：张恩安 张现娥 ZHANG En-an;ZHANG Xian-e(Department of Paediatrics,Kaifeng Children's Hospital,Kaifeng,Henan 475000,China)

机构地区：[1]开封市儿童医院儿内科,河南开封475000

出　　处：《医药论坛杂志》2023年第8期87-90,95,共5页Journal of Medical Forum

摘　　要：目的探讨注射用重组人干扰素α-1b(rhIFNα-1b)、蒙脱石散联合治疗轮状病毒性肠炎(rotavirus enteritis,RVE)患儿的治疗效果,并分析其对肠黏膜损伤、免疫功能的影响。方法选取2020年5月至2022年6月开封市儿童医院收治的105例RVE患儿为研究对象,根据随机数字表法分为单一组52例、联合组53例。单一组予以蒙脱石散治疗,联合组予以rhIFNα-1b联合蒙脱石散治疗。比较两组临床疗效及症状改善时间。统计对比治疗前后两组肠黏膜损伤指标[二胺氧化酶(DAO)、肠型脂肪酸结合蛋白(I-FABP)、淀粉样蛋白A(SAA)]、炎性因子水平[白细胞介素-6(IL-6)、白细胞介素-15(IL-15)、肿瘤坏死因子-α(TNF-α)、高敏C-反应蛋白(hs-CRP)]、免疫功能[免疫球蛋白A(IgA)、免疫球蛋白G(IgG)、CD3^(+)、CD4^(+)]及Toll样受体4(TLR4)/髓样分化因子88(MyD88)/核因子-κB(NF-κB)表达。观察两组不良反应发生情况。结果联合组总有效率92.45%高于单一组75.00%(P<0.05);联合组症状改善时间短于单一组(P<0.05);治疗后联合组DAO、I-FABP、SAA、IL-6、IL-15、TNF-α、hs-CRP及TLR4、MyD88、NF-κB mRNA水平低于单一组,CD3^(+)、CD4^(+)、IgA、IgG水平高于单一组(P<0.05);联合组不良反应发生率7.55%与单一组11.54%比较无明显差异(P>0.05)。结论注射用rhIFNα-1b联合蒙脱石散治疗RVE患儿疗效确切,可改善其临床症状,减轻肠黏膜损伤,抑制炎性反应,提升患儿免疫功能,且具有一定安全性。Objective To investigate the therapeutic effect of the combination of recombinant human interferon alpha-1b(rhIFNα-1b)for injection and montelukast in the treatment of children with rotavirus enteritis(RVE),and to analyze its effect on intestinal mucosal damage and immune function.Methods One hundred and five children with RVE admitted to our hospital from May 2020 to June 2022 were selected for the study,and were divided into 52 cases in the single group and 53 cases in the combined group according to the random number table method.The single group was treated with montelukast and the combined group was treated with rhIFNα-1b combined with montelukast.The clinical efficacy and symptom improvement time of the two groups were compared.Before and after treatment,we compared the intestinal mucosal damage indexes[diamine oxidase(DAO),intestinal fatty acid binding protein(I-FABP),amyloid A(SAA)],inflammatory factor levels[interleukin-6(IL-6),interleukin-15(IL-15),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP)],immune function[immunoglobulin(hs-CRP),immune function[immunoglobulin A(IgA),immunoglobulin G(IgG),CD3^(+),CD4^(+)]and Toll-like receptor 4(TLR4)/myeloid differentiation factor 88(MyD88)/nuclear factor-κB(NF-κB)expression.The occurrence of adverse reactions was observed in both groups.Results The total effective rate of the combined group was 92.45%higher than that of the single group 75.00%(P<0.05);The improvement time of symptoms in the combined group was shorter than that of the single group(P<0.05);The levels of DAO,I-FABP,SAA,IL-6,IL-15,TNF-α,hs-CRP and TLR4,MyD88,NF-κB mRNA in the combined group were lower than that of the single group after treatment,CD3^(+),CD4^(+),IgA and IgG levels were higher than those in the single group(P<0.05);There was no significant difference in the incidence of adverse reactions in the combined group 7.55%compared with 11.54%in the single group(P>0.05).Conclusion The efficacy of rhIFNα-1b injection combined with montelukast in the treatment

关 键 词：重组人干扰素Α-1B 蒙脱石散 轮状病毒性肠炎 疗效 免疫功能 

分 类 号：R725.7[医药卫生—儿科]